Ogawa, Atsushi http://orcid.org/0009-0007-3909-7902
Kawamoto, Hiroshi
Hara, Junichi http://orcid.org/0000-0002-6798-1558
Kikuta, Atsushi http://orcid.org/0009-0006-8868-0435
Ogawa, Chitose
Hiraga, Hiroaki http://orcid.org/0000-0003-1825-1070
Yoshimura, Kenichi
Miyairi, Kazunari
Omori, Reiko
Ro, Tokihiro
Kamei, Yuna
Kimura, Toshimi
Funding for this research was provided by:
Japan Medical Association (jRCT2091220097)
Ohara Pharmaceutical Co., Ltd. (jRCT2080225030)
Article History
Received: 18 December 2023
Accepted: 28 February 2024
First Online: 13 March 2024
Change Date: 23 March 2024
Change Type: Update
Change Details: The original version is updated as the supplementary files have published with track changes.
Declarations
:
: A Ogawa is a speaker honorarium from Chugai Pharmaceutical Co. Ltd. and is an advisor of Ohara Pharmaceutical Co., Ltd.; H Kawamoto is an employee of Ohara Pharmaceutical Co., Ltd; J Hara is an advisor of Ohara Pharmaceutical Co., Ltd.; A Kikuta has received research grants from Scholarship donations by Alfresa Corporation and Nippon Shinyaku Co., Ltd.; C Ogawa has received research grants from Ohara Pharmaceutical Co., Ltd., and is a speaker honorarium from Ohara Pharmaceutical Co., Ltd; H Hiraga has received research grants from Taiho Pharmaceutical Co., Ltd. and Nippon Boehringer Ingelheim Co., Ltd. and is a speaker honorarium from Taiho Pharmaceutical Co., Ltd., Eisai Co., Ltd., Bayer Yakuhin, Ltd., and Kyowa Kirin Co., Ltd.; K Yoshimura declare that they have no conflict of interest; Kazunari Miyairi, Reiko Omori, Tokihiro Ro, and Yuna Kamei are employees of Ohara Pharmaceutical Co., Ltd; T Kimura declare that they have no conflict of interest.